Australia's most trusted source of pharma news
Wednesday, 20 November 2019
Lost Your Access?
Top of the Hill
Not all Aussies are equal
When where you live determines if you live.
She's the boss in Aust pharma
Who has the highest proportion of female managers?
Austs travel OS for CAR-T
Over 20 access life-saving treatment offshore.
SMA to be three-way race
Roche joins Novartis in rally for local access.
Pharma gender pay gap thins
Females earn 10 per cent less than male colleagues.
Local companies target CAR-T
Cancer duo developing new solid tumour therapies.
World's dearest drug arrives
Multi-million dollar SMA 'cure' lands in Australia.
PBAC price targets revealed
Come back only if you cut price, six sponsors told.
Pfizer wins three year war
Finally knocks out Seqirus for major vax populations.
Novartis' new top leader role
Search for country head of new public affairs unit.
Merck unveils new office
Guests, staff gather in Macquarie Park for launch.
Who does PBAC listen to?
Exclusive analysis of July HCP, consumer submissions.
No deal on flu vax says PBAC
Call for higher price falls on deaf ears.
Takeda loses blood battle
Efforts to get biologic funded in HAE prevention fail.
Roche builds lung franchise
Pays USD1.4 billion for new IPF drug.
Biogen caught in PBS slide
All PBS products suffering, including Spinraza.
First copy of Novartis' pill
Juno registers treatment for chronic iron overload.
BMS I-Os target liver
Combo under priority review for HCC in US.
Top of the Hill
The pill or the cure
New gene therapies a challenge for payers.
Events & Conferences
© 2003 - 2019 Lush Media
Pharma in Focus
Jolly Good Design